Why is the ResMed share price sliding on Wednesday?

ResMed shares are coming under selling pressure today.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResMed Inc (ASX: RMD) share price is slipping on Wednesday.

Shares in the S&P/ASX 200 Index (ASX: XJO) healthcare stock closed yesterday trading for $23.76. In morning trade today, shares are swapping hands for $23.46 apiece, down 1.3%.

For some context, the ASX 200 is up 0.1% at this same time.

Here's what's happening.

Cropped shot of a young female scientist working on her computer in the laboratory.

Image source: Getty Images

Why is the ResMed share price slipping?

Much of this morning's sell-off in the ResMed share price has nothing to do with the company itself. Or with any fresh news relating to potentially competing global health advancements in sleep technology, for that matter.

Instead, investors are hitting the sell button because the ASX 200 healthcare stock is trading ex-dividend today.

That means investors buying shares today will no longer be eligible for ResMed's 4.8 US cents per share interim dividend. That income payout will instead go to shareholders who owned the stock at market close yesterday.

It's common for a company's shares to fall on the day they trade ex-dividend, as we see with the ResMed share price today. Similarly, you'll often see shares climb in the lead-up to their ex-dividend date, as income investors snap up shares to secure that payout.

Unlike most ASX 200 dividend shares, ResMed pays out quarterly dividends, generally unfranked.

At the current share price, ResMed trades on a trailing yield of 1.3%.

What's been happening with the ASX 200 healthcare stock?

Management declared the 4.8 US cent per share dividend when ResMed reported its quarterly results on 27 October.

Highlights included a 16% increase in revenue to US$1.1 billion and a 5% boost in income from operations.

Despite some strong metrics, the ResMed share price closed down 4% on the day the company reported.

Looking ahead, ResMed CEO Mick Farrell was optimistic about the company's growth prospects.

"Our ability to meet global demand with technologies … has positioned us well to continue growing across global markets, with particularly strong growth this quarter in Europe, Asia, and beyond," he said.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Broker sees 26% upside in ASX healthcare share behind Chemist Warehouse

Morgans has just upgraded its rating on this ASX healthcare stock due to ongoing share price weakness.

Read more »

Woman using a pen on a digital stock market chart in an office.
Healthcare Shares

Why this ASX healthcare stock is surging while the market sinks on Middle East fears

Avita shares surge as a US government contract boosts sentiment again

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
Healthcare Shares

Should you buy Telix shares after its big US news?

Is this milestone a reason to invest? Let's find out.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Up 31% in a month, why are Telix shares lifting off again on Friday?

ASX investors are piling into Telix shares today. But why?

Read more »

Doctor checking patient's spine x-ray image.
Healthcare Shares

Where is the value amongst ASX healthcare shares?

These three stocks are worth monitoring.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Telix Pharmaceuticals: FDA accepts Pixclara NDA

The FDA has accepted Telix's Pixclara NDA for imaging brain cancer.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Bell Potter says this ASX healthcare stock could rise nearly 200%

The positive announcement has reinforced the broker's recommendation.

Read more »

A man rests his chin in his hands, pondering what is the answer?
Healthcare Shares

CSL shares: 3 reasons to buy and 3 reasons to sell

CSL shares have tumbled again.

Read more »